Suppr超能文献

用“N 端热休克 gp96 蛋白(rNT(gp96))”进行丙型肝炎病毒核心/NS3 蛋白免疫在免疫小鼠中诱导出强烈且持续的 Th1 型细胞因子。

HCV Core/NS3 Protein Immunization with "N-Terminal Heat Shock gp96 Protein (rNT (gp96))" Induced Strong and Sustained Th1-Type Cytokines in Immunized Mice.

作者信息

Hajikhezri Zamaneh, Roohvand Farzin, Maleki Monireh, Shahmahmoodi Shohreh, Amirzargar Ali Akbar, Keshavarz Abolfazl, Seyed Negar, Farahmand Mohammad, Samimi-Rad Katayoun

机构信息

Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran 1449614535, Iran.

Department of Virology, Pasteur Institute of Iran, Tehran 1316943551, Iran.

出版信息

Vaccines (Basel). 2021 Mar 3;9(3):215. doi: 10.3390/vaccines9030215.

Abstract

Feeble cellular responses induced by T cell-based vaccines are a major challenge for the development of an effective vaccine against Hepatitis C virus (HCV) infection. To address this challenge, the potential of N-terminal fragment of gp96 heat shock protein (rNT (gp96) as an adjuvant was evaluated and compared to that of the CpG (as a recognized Th1-type adjuvant) in the formulation of HCV core/NS3 antigens in three immunization strategies of protein/protein, DNA/DNA, and DNA/protein. Immunized mice were evaluated for elicited immune responses in week 3 (W3) and 11 post-immunizations. Our results demonstrated that the protein (subunit) vaccine formulated with rNT (gp96) in protein/protein strategy (core/NS3 + gp96) was significantly more efficient than CpG oligodeoxynucleotides (CpG ODN) formulation and all other immunization strategies in the induction of Th1-type cytokines. This group of mice (core/NS3 + gp96) also elicited a high level of anti-Core-NS3 total immunoglobulin G (IgG) with dominant IgG2a isotype at W3. Thus, the co-administration of recombinant NT (gp96) protein with rHCV proteins might be a promising approach in the formulation of HCV subunit vaccine candidates for induction of high levels of Th1 cytokines and humoral responses.

摘要

基于T细胞的疫苗所引发的微弱细胞反应是开发有效抗丙型肝炎病毒(HCV)感染疫苗的一项重大挑战。为应对这一挑战,在蛋白质/蛋白质、DNA/DNA和DNA/蛋白质三种免疫策略中,对gp96热休克蛋白的N端片段(rNT (gp96))作为佐剂的潜力进行了评估,并与CpG(一种公认的Th1型佐剂)在HCV核心/NS3抗原制剂中的潜力进行了比较。对免疫小鼠在免疫后第3周(W3)和第11周的免疫反应进行了评估。我们的结果表明,在蛋白质/蛋白质策略(核心/NS3 + gp96)中用rNT (gp96)配制的蛋白质(亚单位)疫苗在诱导Th1型细胞因子方面比CpG寡脱氧核苷酸(CpG ODN)制剂和所有其他免疫策略显著更有效。这组小鼠(核心/NS3 + gp96)在W3时也引发了高水平的抗核心-NS3总免疫球蛋白G(IgG),且以IgG2a亚型为主。因此,重组NT (gp96)蛋白与重组HCV蛋白共同给药可能是一种有前景的方法,用于配制HCV亚单位候选疫苗,以诱导高水平的Th1细胞因子和体液反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e415/7999198/b94006a4e44a/vaccines-09-00215-g001a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验